InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,354.81
(
0.17%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

gr8db8

Send PM Follow Ignore
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

gr8db8

Re: None

Thursday, 10/16/2014 12:32:56 PM

Thursday, October 16, 2014 12:32:56 PM

Post# of 80490
"ability of dasatinib and nilotinib to achieve a very deep molecular remission (= 4.5 logs) is encouraging, in light of evolving data that a proportion of patients who achieve and maintain such remissions for at least 1-2 years can discontinue TKI therapy and remain in molecular remission for at least several years."

Until pona can show its effectiveness, dasa and nilo will continue to take the spotlight.

http://www.medscape.com/viewarticle/833129#vp_2
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up